{
    "root": "389f8557-7dbc-40ac-8b68-e8e1a83f6325",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Plerixafor",
    "value": "20240101",
    "ingredients": [
        {
            "name": "PLERIXAFOR",
            "code": "S915P5499N",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_125354"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_26710"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37527"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32145"
        }
    ],
    "indications": {
        "text": "plerixafor injection indicated combination filgrastim mobilize hematopoietic stem cells ( hscs ) peripheral blood collection subsequent autologous transplantation patients non-hodgkin \u2019 lymphoma ( nhl ) multiple myeloma ( mm ) .",
        "doid_entities": [
            {
                "text": "lymphoma (DOID:0060058)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0060058"
            },
            {
                "text": "multiple myeloma (DOID:9538)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9538"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "initiate plerixafor injection treatment patient received filgrastim daily 4 days . ( 2.1 ) repeat plerixafor injection dose 4 consecutive days . ( 2.1 ) dose based patient weight less equal 83 kg : 20 mg dose select dose based 0.24 mg/kg actual body weight . ( 2.1 ) greater 83 kg : select dose based 0.24 mg/kg actual body weight . ( 2.1 ) administer subcutaneous injection approximately 11 hours prior initiation apheresis . ( 2.1 ) renal impairment : creatinine clearance \u226450 ml/min , decrease dose one-third 0.16 mg/kg . ( 2.3 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "plerixafor injection 24 mg/1.2 ml ( 20 mg/ml ) sterile , preservative-free , clear , colorless pale-yellow solution supplied clear glass single-dose vial . ndc number : 0480-4320-01 store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0 f ) [ usp controlled room temperature ] .",
    "adverseReactions": "plerixafor injection contraindicated patients history hypersensitivity plerixafor [ ( 5.1 ) ] . anaphylactic shock occurred plerixafor injection .",
    "indications_original": "Plerixafor Injection is indicated in combination with filgrastim to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin\u2019s lymphoma (NHL) or multiple myeloma (MM).",
    "contraindications_original": "Initiate Plerixafor Injection treatment after the patient has received\u00a0filgrastim once daily for 4 days. ( 2.1 ) Repeat Plerixafor Injection dose up to 4 consecutive days. ( 2.1 ) Dose based on patient weight Less than or equal to 83 kg: 20 mg dose or select dose based on 0.24 mg/kg actual body weight. ( 2.1 ) greater than 83 kg: select dose based on 0.24 mg/kg actual body weight. ( 2.1 ) Administer by subcutaneous injection approximately 11 hours prior to initiation of apheresis. ( 2.1 ) Renal impairment: If creatinine clearance is \u226450 mL/min, decrease dose by one-third to 0.16 mg/kg. ( 2.3 )",
    "warningsAndPrecautions_original": "Plerixafor Injection 24 mg/1.2 mL (20 mg/mL) is a sterile, preservative-free, clear, colorless to pale-yellow solution supplied in a clear glass single-dose vial.\n                  NDC Number: 0480-4320-01\n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); excursions permitted to 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0 F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "Plerixafor Injection is contraindicated in patients with a history of hypersensitivity to plerixafor [see Warnings and Precautions (5.1)]. Anaphylactic shock has occurred with use of Plerixafor Injection.",
    "drug": [
        {
            "name": "Plerixafor",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_125354"
        }
    ]
}